Richard Kim

Richard Kim has nearly 20 years of biotechnology experience in both clinical development and medical affairs (phase I to IV) with demonstrated accomplishments in a wide range of indications, including multiple sclerosis, psoriasis, restless legs syndrome, amyotrophic lateral sclerosis, alcohol use disorder, and post-herpetic neuralgia, and direct experience working with currently approved products such as TYSABRI, Cladribine, Rebif, and Horizant. Prior to joining ImStem Biotechnology, he was the chief medical officer at Xenoport, where he worked on gabapentin enacarbil and a second-generation fumaric acid candidate called XP23829, which was pursued multiple sclerosis and psoriasis. And prior to XenoPort, his career accomplishments spanning Elan Pharmaceuticals, Biogen Idec, and EMD Serono included clinical development and medical affairs leadership roles working with alpha-4 integrin inhibitors, PML risk stratification, Tysabri, Cladribine, and Rebif. After graduating from Tulane University Medical School, he completed his neurology residency at Stanford University, and to date remains a diplomat of the American Academy of Neurology.